Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Nov;107(3):697–704. doi: 10.1111/j.1476-5381.1992.tb14509.x

Identification of alpha 1-adrenoceptor subtypes in the rat vas deferens: binding and functional studies.

T Ohmura 1, M Oshita 1, S Kigoshi 1, I Muramatsu 1
PMCID: PMC1907766  PMID: 1361871

Abstract

1. The alpha 1-adrenoceptor subtypes of the prostatic and epididymal portion of rat vas deferens were characterized in binding and functional experiments. 2. In saturation experiments, [3H]-prazosin bound to two distinct affinity sites in the epididymal portion of rat vas deferens (pKD = 10.1 +/- 0.13 and 9.01 +/- 0.15, Bmax = 507 and 1231 fmol mg-1 protein, respectively). In the prostatic portion [3H]-prazosin bound to a single affinity site (pKD = 9.82 +/- 0.04, Bmax = 924 fmol mg-1 protein). 3. In the displacement experiments, unlabelled prazosin displaced biphasically the binding of 200 pM [3H]-prazosin to the epididymal portion; the resulting two pKI values were consistent with the affinity constants obtained in the saturation experiments. WB4101 (2-(2,6-dimethoxy-phenoxyethyl)-amino-methyl-1,4-benzodioxane) and benoxathian also discriminated the two affinity sites in the epididymal portion and the population of low affinity sites for the three antagonists was approximately 40%. On the other hand, the prostatic portion predominantly showed a single affinity site for prazosin, WB4101 and benoxathian, although the presence of a small proportion (less than 10%) of the low affinity site could be detected. HV723 (alpha-ethyl-3,4,5-trimethoxy-alpha-(3-((2-(2-methoxyphenoxy)ethyl)-a min o)- propyl) benzeneacetonitrile fumarate) displaced the [3H]-prazosin binding monophasically with a low affinity in both halves. 4. Pretreatment with chlorethylclonidine (CEC) at concentrations higher than 1 microM inhibited 700 pM [3H]-prazosin binding to the prostatic portion by approximately 50%. However, the inhibition in the epididymal portion was much less (approximately 21% at 50 microM CEC).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
701

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Badia A., Sallés J. Effects of St-587 on the alpha-adrenoceptors in the bisected rat vas deferens. J Pharm Pharmacol. 1989 Sep;41(9):612–616. doi: 10.1111/j.2042-7158.1989.tb06541.x. [DOI] [PubMed] [Google Scholar]
  3. Blakeley A. G., Brown D. A., Cunnane T. C., French A. M., McGrath J. C., Scott N. C. Effects of nifedipine on electrical and mechanical responses of rat and guinea pig vas deferens. Nature. 1981 Dec 24;294(5843):759–761. doi: 10.1038/294759a0. [DOI] [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  5. Brown D. A., Docherty J. R., French A. M., MacDonald A., McGrath J. C., Scott N. C. Separation of adrenergic and non-adrenergic contractions to field stimulation in the rat vas deferens. Br J Pharmacol. 1983 Jun;79(2):379–393. doi: 10.1111/j.1476-5381.1983.tb11010.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bülbring E., Tomita T. Catecholamine action on smooth muscle. Pharmacol Rev. 1987 Mar;39(1):49–96. [PubMed] [Google Scholar]
  7. De Lean A., Hancock A. A., Lefkowitz R. J. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol. 1982 Jan;21(1):5–16. [PubMed] [Google Scholar]
  8. Han C., Abel P. W., Minneman K. P. Alpha 1-adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle. Nature. 1987 Sep 24;329(6137):333–335. doi: 10.1038/329333a0. [DOI] [PubMed] [Google Scholar]
  9. Han C., Abel P. W., Minneman K. P. Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine. Mol Pharmacol. 1987 Oct;32(4):505–510. [PubMed] [Google Scholar]
  10. Hanft G., Gross G. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol. 1989 Jul;97(3):691–700. doi: 10.1111/j.1476-5381.1989.tb12005.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kasuya Y., Suzuki N. Variation of postjunctional natures along the length of the rat vas deferens as a cause of regional difference in the sensitivity to norepinephrine. Arch Int Pharmacodyn Ther. 1979 Sep;241(1):24–31. [PubMed] [Google Scholar]
  12. Kenakin T. P. The relative contribution of affinity and efficacy to agonist activity: organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptors. Br J Pharmacol. 1984 Jan;81(1):131–141. doi: 10.1111/j.1476-5381.1984.tb10753.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lomasney J. W., Cotecchia S., Lefkowitz R. J., Caron M. G. Molecular biology of alpha-adrenergic receptors: implications for receptor classification and for structure-function relationships. Biochim Biophys Acta. 1991 Oct 26;1095(2):127–139. doi: 10.1016/0167-4889(91)90075-9. [DOI] [PubMed] [Google Scholar]
  14. Lomasney J. W., Cotecchia S., Lorenz W., Leung W. Y., Schwinn D. A., Yang-Feng T. L., Brownstein M., Lefkowitz R. J., Caron M. G. Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. J Biol Chem. 1991 Apr 5;266(10):6365–6369. [PubMed] [Google Scholar]
  15. MacDonald A., McGrath J. C. The distribution of adrenoceptors and other drug receptors between the two ends of the rat vas deferens as revealed by selective agonists and antagonists. Br J Pharmacol. 1980;71(2):445–458. doi: 10.1111/j.1476-5381.1980.tb10957.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McGrath J. C. Adrenergic and 'non-adrenergic' components in the contractile response of the vas deferens to a single indirect stimulus. J Physiol. 1978 Oct;283:23–39. doi: 10.1113/jphysiol.1978.sp012486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McGrath J., Wilson V. Alpha-adrenoceptor subclassification by classical and response-related methods: same question, different answers. Trends Pharmacol Sci. 1988 May;9(5):162–165. doi: 10.1016/0165-6147(88)90030-2. [DOI] [PubMed] [Google Scholar]
  18. Minneman K. P. Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. Pharmacol Rev. 1988 Jun;40(2):87–119. [PubMed] [Google Scholar]
  19. Molinoff P. B., Wolfe B. B., Weiland G. A. Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes. Life Sci. 1981 Aug 3;29(5):427–443. doi: 10.1016/0024-3205(81)90208-3. [DOI] [PubMed] [Google Scholar]
  20. Moore P. K., Griffiths R. J. Pre-synaptic and post-synaptic effects of xylazine and naphazoline on the bisected rat vas deferens. Arch Int Pharmacodyn Ther. 1982 Nov;260(1):70–77. [PubMed] [Google Scholar]
  21. Morrow A. L., Creese I. Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. Mol Pharmacol. 1986 Apr;29(4):321–330. [PubMed] [Google Scholar]
  22. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  23. Muramatsu I., Kigoshi S., Ohmura T. Subtypes of alpha 1-adrenoceptors involved in noradrenaline-induced contractions of rat thoracic aorta and dog carotid artery. Jpn J Pharmacol. 1991 Dec;57(4):535–544. doi: 10.1254/jjp.57.535. [DOI] [PubMed] [Google Scholar]
  24. Muramatsu I., Kigoshi S., Oshita M. Two distinct alpha 1-adrenoceptor subtypes involved in noradrenaline contraction of the rabbit thoracic aorta. Br J Pharmacol. 1990 Nov;101(3):662–666. doi: 10.1111/j.1476-5381.1990.tb14137.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Muramatsu I., Ohmura T., Kigoshi S., Hashimoto S., Oshita M. Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol. 1990 Jan;99(1):197–201. doi: 10.1111/j.1476-5381.1990.tb14678.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Muramatsu I., Ohmura T., Oshita M. Comparison between sympathetic adrenergic and purinergic transmission in the dog mesenteric artery. J Physiol. 1989 Apr;411:227–243. doi: 10.1113/jphysiol.1989.sp017570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Muramatsu I., Oshita M., Yamanaka K. Selective alpha-2 blocking action of DG-5128 in the dog mesenteric artery and rat vas deferens. J Pharmacol Exp Ther. 1983 Oct;227(1):194–198. [PubMed] [Google Scholar]
  28. Oshita M., Iwanaga Y., Hashimoto S., Morikawa K., Muramatsu I. Pharmacological studies on the selectivity of HV-723, a new alpha-1 adrenoceptor antagonist. Jpn J Pharmacol. 1988 Jul;47(3):229–235. doi: 10.1254/jjp.47.229. [DOI] [PubMed] [Google Scholar]
  29. Oshita M., Kigoshi S., Muramatsu I. Three distinct binding sites for [3H]-prazosin in the rat cerebral cortex. Br J Pharmacol. 1991 Dec;104(4):961–965. doi: 10.1111/j.1476-5381.1991.tb12533.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sallés J., Badia A. Mechanisms underlying the differential sensitivity to alpha 1-adrenoceptor activation in the bisected rat vas deferens. Br J Pharmacol. 1991 Feb;102(2):439–445. doi: 10.1111/j.1476-5381.1991.tb12192.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Schwinn D. A., Lomasney J. W., Lorenz W., Szklut P. J., Fremeau R. T., Jr, Yang-Feng T. L., Caron M. G., Lefkowitz R. J., Cotecchia S. Molecular cloning and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype. J Biol Chem. 1990 May 15;265(14):8183–8189. [PubMed] [Google Scholar]
  32. Sneddon P., Burnstock G. Inhibition of excitatory junction potentials in guinea-pig vas deferens by alpha, beta-methylene-ATP: further evidence for ATP and noradrenaline as cotransmitters. Eur J Pharmacol. 1984 Apr 13;100(1):85–90. doi: 10.1016/0014-2999(84)90318-2. [DOI] [PubMed] [Google Scholar]
  33. Vardolov L., Pennefather J. N. Regional variation in the distribution of alpha-adrenoreceptors in the vas deferens of the rat. Arch Int Pharmacodyn Ther. 1976 Jun;221(2):212–212. [PubMed] [Google Scholar]
  34. Wilson V. G., Brown C. M., McGrath J. C. Are there more than two types of alpha-adrenoceptors involved in physiological responses? Exp Physiol. 1991 May;76(3):317–346. doi: 10.1113/expphysiol.1991.sp003501. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES